Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsThree-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialStudy of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsReal-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinStudy of BMS-650032 With Peginterferon Alfa-2a Plus RibavirinRapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C VirusFood Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (DigoxinDrug Interaction & Methadone & BuprenorphineUNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C VirUNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)GenotPilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin RegimenImpact of HCV Treatment on Neurocognitive Functions and Brain MetabolismEffect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV PatientsAsunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis CStudy of Drug Combination on Pharmacokinetics in Healthy VolunteersTo Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletTherapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and RosuvastatinDrug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null RespondersA Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsDrug Interaction Oral Contraceptive Pill (OCP)An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) SubjectHepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareDrug-Drug Interaction Study in Healthy SubjectsA Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsThe Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal FailureA Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionTriple DAAs Regimen in Treating Non-cirrhotic HCV GT1b SubjectsA Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and AsunaprevirShort Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCVUNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CNew Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis CStudy of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease
P4844
Q63316129-17E0420E-EE24-4112-AF98-B2C87F0F3153Q63318669-F7E9935F-A639-42FA-A728-AEE6B965B4BEQ63320192-534E9A19-0BD3-460B-BEAC-183A6B105FBFQ63320725-4F3B3B73-2EB5-4CA2-923D-A493BDAA86CAQ63581313-BFEF6851-DBDD-48B8-B508-4092FE142E0CQ63813567-B71D4EE2-0CCE-4711-8FCD-175C2C3757A9Q63837488-2BE6F10A-F660-4BA4-883B-8AF2480A95CBQ64220052-B63D3FAA-1D81-4FCB-936C-FCE703C873C1Q64220270-49560D9C-FCDF-4B49-9AFE-9C1EFBC3003FQ64348533-912C77E0-46E3-4909-A5A8-46845DBC830FQ64348562-98F1B117-5E01-42F0-963D-CDBE08B91C9CQ64352602-F29B5893-25C3-4016-983B-30851476E08FQ64352917-B46D50BE-9E7C-4A79-80A0-1FFAF70AE626Q64597931-737E6C8A-E3AE-4C1E-8A2B-A07860030F28Q64598706-D9A0B59B-ABF1-49D5-B8F8-0B9DBD56B4F3Q64599766-6475BDD2-FEC5-4B40-BB97-B12B11D833AFQ64602463-7B787DC3-217C-4533-9647-77C329BDB562Q64611408-DC3208B8-33C8-4EFF-9C81-91AE90D72C1EQ64611752-BFB061E1-9258-4B48-8428-EB7F70B92F96Q64611870-E9D11CB2-7B09-4AD0-BC07-5645DF57BE09Q64612107-9A0B3720-9E72-4B65-A4D4-E146511304A0Q64612230-E1E15C42-AA2F-4B3B-9C62-46A6CFFC0B7CQ64637592-D04D6510-A441-4A2F-843C-EBD9266A600AQ64638937-4D0900B3-5F4C-483E-8CF4-A8B2372E051AQ64656883-6A88F8B4-C4EE-49D6-89AE-6BF62B3D1238Q64657352-F18119F5-FDFF-48BD-B6BC-672FEDB7D5B5Q64658697-80CDFD69-F5D8-44E0-AAD3-4C9B822E48D0Q64659651-CB085CB6-6F46-4B17-9201-A39BED56E1D1Q64675897-B70B0933-22D1-4206-B187-546AC4BCB8DCQ64717271-0D239930-98E1-41F3-BA3F-ED48D890AC5BQ65316189-7B30EA0A-909C-4141-843F-27BFF7F93BE0Q65344655-3A24130F-D7EB-4FAD-8B6C-0A0BB08FB328Q65346233-AAFE1284-0340-44F4-A9D4-DAAF965BBFCDQ65353498-E5479DF4-4ABA-49A5-8939-BED2E45809D0Q65353701-795450C3-8123-4E1E-B206-2599D7C117B6Q65354393-8DB7F5E3-56D5-42E6-969F-FE35BE4C1BCBQ65360264-06E79FE0-E28C-4F4B-82D4-A1270270E82AQ65360365-673CE343-AD4F-410D-AAF4-5DFD528C0F5FQ65361009-E3642FB6-0A11-4B68-8CE1-BC3956FE5215Q65361604-D44063F1-9AC2-48C6-B32A-C1446EEBB95F
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Asunaprevir
@fr
Asunaprevir
@sh
Asunaprevir
@sr
Asunaprevir
@vi
asunaprevir
@en
Асунапревир
@ru
アスナプレビル
@ja
type
label
Asunaprevir
@fr
Asunaprevir
@sh
Asunaprevir
@sr
Asunaprevir
@vi
asunaprevir
@en
Асунапревир
@ru
アスナプレビル
@ja
altLabel
Asunaprevir
@en
prefLabel
Asunaprevir
@fr
Asunaprevir
@sh
Asunaprevir
@sr
Asunaprevir
@vi
asunaprevir
@en
Асунапревир
@ru
アスナプレビル
@ja
P31
P638
P486
P592
P6366
P661
P662
P665
P683
P117
P2017
CC(C)(C)[C@@H](C(=O)N1C[C@@H]( ...... C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
P2067
P231
630420-16-5
P232
P233
CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC ...... C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
P234
1S/C35H46ClN5O9S/c1-9-19-16-35 ...... 44)/t19-,21-,25+,27-,35-/m1/s1
P235
XRWSZZJLZRKHHD-WVWIJVSJSA-N
P2566
100.206.482